Visual and ocular outcome in children after prenatal exposure to antiepileptic drugs

K T Fahnehjelm1, K Wide, J Ygge

  • 1Department of Clinical Sciences, Karolinska Institute, Huddinge University Hospital, Sweden. kristina.fahnehjelm@klinvet.ki.se

Insights

Antiepileptic drug (AED) treatment during pregnancy, particularly monotherapy, appears safe for fetal eye development. This study found no major ophthalmological abnormalities in children exposed to well-controlled AEDs.

Area of Science:

  • Ophthalmology
  • Neurology
  • Teratology

Background:

  • Epilepsy affects women of childbearing age.
  • Antiepileptic drugs (AEDs) are often necessary during pregnancy.
  • Concerns exist regarding potential teratogenic effects of AEDs on fetal development, including ocular structures.

Purpose of the Study:

  • To investigate the incidence of structural and functional ophthalmological abnormalities in offspring of women with epilepsy treated with antiepileptic drugs (AEDs) during pregnancy.
  • To assess the safety of well-controlled AED treatment on ocular development.
  • To compare ophthalmological outcomes in children exposed to AEDs versus controls.

Main Methods:

  • Prospective study including 43 children prenatally exposed to AEDs and 47 controls.
  • Blinded ophthalmological examinations were conducted.
  • Fundus photography was utilized to assess ocular structures.

Main Results:

  • No major eye anomalies were detected in the AED-exposed group, except for one child with nystagmus and low vision.
  • Exposed children exhibited slightly lower visual acuity in the eye with the lowest acuity (p < 0.05).
  • No other significant ophthalmological differences were observed between exposed and control groups.

Conclusions:

  • Well-controlled antiepileptic drug (AED) treatment during pregnancy, especially monotherapy, does not appear to cause major adverse effects on eye development.
  • The findings support the safety of carefully managed AED regimens for pregnant women with epilepsy.
  • Further research may explore subtle visual function differences.
Abstract

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...